ArticleInternational journal of nanomedicine2024
Loratadine Loaded Chitosan Tannic Acid Nanoparticles as Anti-Proliferative Agent Against Breast Cancer: In-silico, in-vitro and Cell Studies.
Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting histamine signaling: repurposing antihistamines for cancer chemotherapy and immunotherapy.Archives of pharmacal research · 2026Review
- Combinatorial Anti-Mitotic Activity of Loratadine/5-Fluorouracil Loaded Zein Tannic Acid Nanoparticles in Breast Cancer Therapy: In silico, in vitro and Cell Studies.International journal of nanomedicine · 2026Article
- Polymer Nanoparticles Advancements for Gynecological Cancers.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to prepare Loratadine-loaded chitosan/tannic acid nanoparticles (LOR-CS/TAN NPs) through ionic gelation to be used as an anti-proliferative agent to aid in overcoming breast cancer propagation. Methods: First, in-silico virtual screening was carried out to select the most appropriate anti-histaminic drug based on its inhibitory effect on the H1-histamine receptor, resulting in the selection of Loratadine (LOR). Molecular interaction between LOR with chitosan (CS), a positively charged polymer, and hyaluronan, a negatively charged polymer, was investigated separately through molecular docking, leading to the selection of CS. Optimization was carried out using Box Behnken Design, with concentrations of CS, LOR, and tannic acid (TAN) as independent variables. The optimized nanoparticles were then examined through morphological and physicochemical studies. Cell studies against the MCF-7 breast cancer cell line were conducted to assess cytotoxicity, cell cycle, apoptosis, and necrosis. Results: The optimum formulation was determined to be CS (0.2% w/v), LOR (1:2 weight ratio to CS), and TAN (1:30.6 weight ratio to CS). The optimized LOR-CS/TAN NPs exhibited a size of 283 nm, a polydispersity index (PDI) of 0.102, and an entrapment efficiency of 78%, along with sustained drug release for 24 hours. The results demonstrated that LOR-CS/TAN NPs possess higher anti-cancer activity compared to free LOR. This enhanced activity is attributed to the synergistic effect of the drug and the designed nanoparticle, particularly due to the presence of tannic acid. Conclusion: In conclusion, Loratadine-loaded chitosan/tannic acid nanoparticles (LOR-CS/TAN NPs) demonstrated enhanced anti-cancer activity against the MCF-7 breast cancer cell line. The synergistic effect of Loratadine and the nanoparticle system, particularly due to the presence of tannic acid, resulted in higher cytotoxicity compared to free Loratadine. These findings suggest that LOR-CS/TAN NPs have significant potential as a novel anti-proliferative agent for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.